<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="82261">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01849848</url>
  </required_header>
  <id_info>
    <org_study_id>2011004</org_study_id>
    <nct_id>NCT01849848</nct_id>
  </id_info>
  <brief_title>Study of SyB L-0501 to Treat Relapsed/Refractory Multiple Myeloma</brief_title>
  <official_title>A Multicenter, Open-Label Phase II Study of SyB L-0501 in Patients With Relapsed/Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SymBio Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SymBio Pharmaceuticals</source>
  <oversight_info>
    <authority>Japan: Pharmaceuticals and Medical Devices Agency</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the antitumor efficacy and safety of bendamustine
      (SyB L-0501: 90 mg/m2/day) for a maximum of 6 cycles (1 cycle: intravenous administration
      for 2 consecutive days and 26-day observation period) in patients with relapsed/refractory
      multiple myeloma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2011</start_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Response rate [stringent CR (sCR)+complete response (CR)+very good PR (VGPR)+partial response (PR)]based on International Myeloma Working Group (IMWG) criteria</measure>
    <time_frame>up to around 44 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The criteria for sCR, CR, VGPR, and PR based on IMWG are as below
sCR: Fulfills CR criteria as well as all of the following conditions
Normal free light chain (FLC) ratio(κ/λ)
Disappearance of clonal cells in bone marrow by immunohistochemistry or immunofluorescence
CR: Fulfills all of the following criteria
Negative immunofixation of serum and urine M-protein
&lt;5% plasma cells in bone marrow
Disappearance of any soft tissue plasmacytoma
VGPR: Fulfills at least one of the following criteria
Serum and urine M-protein detectable by immunofixation but not electrophoresis
≥90% reduction in serum M-protein and 24-hour M-protein excretion amount in urine &lt;0.1 g/24 hour
PR: Fulfills the following criteria
≥50% reduction in serum M-protein, and ≥90% reduction in urine M-protein, urine M-protein excretion amount is reduced to &lt; 0.2 g/24hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate (sCR+CR) based on IMWG criteria</measure>
    <time_frame>up to around 44 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete response (CR) based on the Blade criteria</measure>
    <time_frame>up to around 44 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The criteria for CR based on the Blade are as below
CR requires all of the followings:
Absence of the original monoclonal paraprotein in serum and urine by immunofixation, maintained for a minimum of 6 weeks
&lt;5% plasma cells in a bone marrow aspirate and also on trephine bone biopsy
No increase in size or number of lytic bone lesions
Disappearance of soft tissue plasmacytomas</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate (CR+PR) based on the Blade criteria</measure>
    <time_frame>up to around 44 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The criteria for PR based on the Blade are as below
PR requires 1. or all of the others:
Some, but not all, of the criteria for CR are fulfilled
≥50% reduction in the level of the serum monoclonal paraprotein, maintained for a minimum of 6 weeks
Reduction in 24 h urinary light chain excretion either by ≥90% or to &lt;200 mg, maintained for a minimum of 6 weeks
For patients with non-secretory myeloma only, ≥50% reduction in plasma cells in a bone marrow aspirate and on trephine biopsy
≥50% reduction in the size of soft tissue plasmacytomas
No increase in size or number of lytic bone lesions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>up to around 44 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Using the registration date as the start date, PFS with relapse/recurrence or progression, and death regardless of the cause as events are to be summarized using the Kaplan-Meier estimator and the 50% point according to the Greenwood's formula and the 95% confidence interval are to be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Treatment Failure (TTF)</measure>
    <time_frame>up to around 44 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Using the registration date as the start date, TTF with relapse/recurrence or progression, death regardless of the cause, and early discontinuation of treatment as events are to be summarized using the Kaplan-Meier estimator and the 50% point according to the Greenwood's formula and 95% confidence interval are to be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>up to around 44 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>From initial response (PR or higher), DOR with relapse/recurrence or progression, and death, regardless of cause, as events, are to be summarized using the Kaplan-Meier estimator and the 50% point according to the Greenwood's formula and 95% confidence interval are to be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>up to around 44 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Using the registration date as the start date, OS with death, regardless of the cause, as events, are to be summarized using the Kaplan-Meier estimator and the 50% point according to the Greenwood's formula and 95% confidence interval are to be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>up to around 44 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>All adverse events occurring during the administration of the investigational product are to be examined for safety by cross tabulation lists and tables of incidence from the viewpoint of relationship with the drug, disease severity and medicine treated group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Abnormality (Grade ≥3) in Laboratory Test Values</measure>
    <time_frame>up to around 44 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Abnormalities in laboratory test values in overall study period were analyzed. Severity of abnormalities were evaluated using Common Terminology Criteria for Adverse Events (CTCAE). grade 1 : mild grade 2 : moderate grade 3 : severe or medically significant but not immediately life-threatening grade 4 : life threatening or disabling grade 5 : death related to adverse event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Abnormalities (Grade ≥3) in Laboratory Test Values</measure>
    <time_frame>up to around 44 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Abnormalities in laboratory test values in overall study period were analyzed. Severity of abnormalities were evaluated using CTCAE.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Relapsed/Refractory Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>SyB L-0501</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SyB L-0501</intervention_name>
    <description>The administration of SyB L-0501 at 90 mg/m2/day by 60-minute intravenous infusion for 2 consecutive days followed by 26 days of monitoring. This is considered to be one cycle and may be repeated up to 6 times. Dose reduction or discontinuation is permitted from the second cycle as necessary according to adverse events and the results of monitoring during the previous cycle.</description>
    <arm_group_label>SyB L-0501</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients who are diagnosed with multiple myeloma on the basis of the response
             criteria of the International Myeloma Working Group (IMWG) and confirmed to meet one
             or more of the following criteria:

             (definition of progression according to the IMWG response criteria)

               -  25% or more increase compared to baseline for the following values

                    -  Serum M-protein level (however, the absolute value is 0.5 g/dL or higher)

                    -  Urine M-protein level (however, absolute value is 200 mg/24 hours or
                       higher)

                    -  For lesions without measurable serum or urine M-protein values.
                       involved/uninvolved FLC ratio (however, absolute value is 10 mg/dL or
                       higher)

               -  Clear appearance of new bone lesions or soft tissue plasmacytoma or apparent
                  growth in size of current bone lesions or soft tissue plasmacytoma

               -  Appearance of hypercalcemia (corrected calcium level ≥ 11.5 mg/dL and if
                  determined to be caused solely by myelomas)

          2. Patients with measurable lesions (meets at least one of the following two criteria

               -  Serum M-protein [Immunoglobulin G (IgG)≥ 1.0 g/dL, Immunoglobulin A (IgA) ≥ 0.5
                  g/dL, Immunoglobulin D (IgD) ≥ 0.1 g/dL)

               -  Urine M-protein ≥ 200 mg/24 hours

          3. Patients who meet either one of the following items for all prior chemotherapy using
             proteasome inhibitors, Immunomodulatory Drugs (IMiDs) (thalidomide or lenalidomide)
             or alkylating agents.

               -  No response*

               -  Relapse/recurrence after response*

               -  Intolerance

               -  Not applicable (reason can be confirmed in the source document) because of
                  predicted aggravation of complications (neurotoxicity, etc.) * Patients whose
                  disease has progressed based on the IMWG response criteria after receiving the
                  most recent therapy

          4. Patients who have undergone a washout period of more than 3 weeks after the end of
             the previous therapy and determined not to be under the effect of previous treatment
             (antitumor effectiveness).

          5. Patients who are expected to survive for at least 3 months

          6. Patients aged from 20 to 79 years at the time of interim registration

          7. Performance Status (P.S.) of 0 to 125. However, P.S. 2 due to pain from lytic bone
             lesions is acceptable

          8. Patients with adequately maintained organ functions (e.g., bone marrow, heart, lung,
             liver, and kidney functions)

               -  Neutrophil count:≥ 1,500 /mm3

               -  Platelet count:≥ 75,000 /mm3

               -  Albumin:≥ 2.5 g /dL

               -  Aspartate aminotransferase(AST) Glutamic oxaloacetic transaminase(GOT):  &lt; than
                  3.0 times the upper limit of normal range for the site

               -  Alanine aminotransferase (ALT) Glutamic pyruvic transaminase(GPT):  &lt; than 3.0
                  times the upper limit of normal range for the site

               -  Total bilirubin:  &lt; than 1.5 times the upper limit of normal range for the site

               -  Serum creatinine:  &lt; than 3.0 times the upper limit of normal range for the site

               -  Partial pressure of O2(PaO2) ≥ 65 mmHg

               -  No abnormalities which require treatment are detected on ECG

               -  Left ventricular ejection fraction(LVEF)(echocardiography): ≥ 55%

          9. Patients who have provided written consent for participation in this study

        Exclusion Criteria:

          1. Patients with apparent infections (including viral infections)

          2. Patients with serious complications (hepatic or renal dysfunction, etc.)

          3. Patients with complications or medical history of serious cardiac disease (e.g.,
             myocardial infarction, ischemic heart disease) within 2 years of the date of interim
             registration or patients with arrhythmias that require treatment

          4. Patients with serious gastrointestinal symptoms (e.g., severe nausea, vomiting, or
             diarrhea)

          5. Patients positive for Hepatitis B surface(HBs) antigen, Hepatitis C virus (HCV)
             antibody, or HIV antibody

          6. Patients with serious bleeding tendencies (e.g., disseminated intravascular
             coagulation: DIC)

          7. Patients with, or confirmed in the past to have had, interstitial pneumonia,
             pulmonary fibrosis, or pulmonary emphysema which requires treatment.

          8. Patients with a complication of apparent cardiac amyloidosis

          9. Patients with infiltration to the central nervous system (CNS) or patients with
             clinical symptoms of suspected infiltration to the CNS,

         10. Patients with active multiple primary cancer

         11. Patients with, or confirmed in the past to have had, autoimmune hemolytic anemia

         12. Patients who have received this investigational product in the past

         13. Patients who have received allogeneic stem cell transplants in the past. (patients
             who have received autologous stem cell transplantation are acceptable)

         14. Patients who received cytokine preparations such as erythropoietin or granulocyte
             colony stimulating factor (G-CSF) or blood transfusions within 1 week prior to the
             examination conducted before interim registration for this study

         15. Patients who received other investigational products or unapproved medications within
             3 months before interim registration for this study

         16. Patients with prior allergies to medications that are similar to this investigational
             product (e.g., alkylating agents, or purine-nucleoside derivatives) or mannitol

         17. Patients with drug addiction, narcotics addiction, and/or alcohol dependency

         18. Patients who are pregnant, who may possibly be pregnant, or lactating

         19. Patients who do not agree to practice contraception for the following periods:

             Male: During investigational product administration and until 6 months after final
             administration Female: During investigational product administration and until 4
             months after final administration

         20. Patients otherwise judged by the investigator or sub-investigator to be unsuitable
             for inclusion in this study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Takashi Motoyama</last_name>
    <phone>+81-3-5472-1127</phone>
    <email>tmotoyama.117@symbiopharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Toshihiko Nagase</last_name>
    <phone>+81-3-5472-1127</phone>
    <email>tnagase.331@symbiopharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <address>
        <city>Chuo-ku</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Isehara</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Koto-ku</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Nagoya</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Niigata</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Okayama</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Sapporo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Sendai</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Shibukawa</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Shibuya-ku</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Tokushima</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Utsunomiya</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>May 8, 2013</lastchanged_date>
  <firstreceived_date>April 17, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
